Dr Reddy's shrugged off recent volatility on Wednesday and moved tenaciously on filing new gernerics with the US FDA.
'Nothing in this world is permanent. So also in business.' 'And more so in family businesses where family issues often influence business decisions,' point out S Subramanian and Nupur Pavan Bang.
Maggi banned in Delhi for 15 days.
The recalled drug bottles were distributed by Caraco Pharmaceutical Laboratories, Ltd in the US while manufactured in India by Sun Pharmaceutical Industries Ltd.
Accenture -- considered as one of the top-most employers in India among the global technology services companies -- is believed to have over 150,000 workers in India, next to IBM.
The drug is licensed to Ranbaxy Laboratories from Cipher Pharmaceuticals Inc of Mississauga, Ontario. It is currently protected by two issued patents listed in the FDA's approved drug products list, which expire in September 2021, the company said in a statement.
Viveka Kumar lists the factors you need to keep in mind.
An International Policy Network report in 2010 found that seven per cent of drugs bought from wholesale traders were substandard, and 3.6 per cent of the drugs from traders contained no active ingredient whatsoever.
.jpg)
As per the media report, the US Food and Drug Administration is learnt to have issued a Form 483 to the company's manufacturing facility at Mohali a few months ago after finding deviations from norms during an inspection of the plant.
According to the petition copies, Hospira has alleged that Aurobindo's Abbreviated New Drug Application (ANDA) to make generic version of dexmedetomidine hydrochloride injection would infringe its patented drug Precedex.
The state government had in the first week of June banned Maggi sale in the state after the product failed the food safety test.
'Sharapova has been a US resident since early in her career, which does bring in a question of how or why she is using a drug that is not licensed there'
A huge stock of Maggi noodles was destroyed by Nestle after the ban was imposed by the food regulators.
It hopes to turn around Ranbaxy within four years of closing the deal by improving efficiency and resolving all regulatory issues
Sun Pharma profit down 30% over compliance costs, lower sales.
Nestle now has less than two weeks to convince the regulator why product approval for its noodles should not be withdrawn
Pharma major Ranbaxy Laboratories has set aside Rs 257.4 crore (Rs 2.57 billion) towards the financial impact of a US ban on import of products made at its plant at Toansa.
IT, pharma and FMCG stocks are the top performers in 2013.
The company spokesperson expressed disappointment with the "unprecedented step of filing of a complaint before the NCDRC"
According to Munjal, there is an opportunity for somebody who comes from a not for profit background in health care to do something.
While the US health regulator did not specify details for issuing the alert, it said 'detention without physical examination may be appropriate when an FDA inspection has revealed that a firm is not operating in conformity with current good manufacturing practices'.
While Reliance Retail did not comment, sources said the company will have to follow order, at least in Delhi.
.jpg)
The report comes at a time when the government is trying to clear pending FDI proposals, which include various planned investments in this sector.
The combined sales of the branded versions of the products in the US is about $3.5 billion.
Amneal Pharmaceuticals is set to pip Sun Pharma as the fifth largest generics maker in the US, reports Sohini Das.
In India, thousands of lives are lost every year because of unavailability of organs
4 Ranbaxy facilities in India have been barred from exporting to US.
DRL launched four new products in North America during the previous quarter.
market, was today seized from an illegal drug manufacturing unit in Jalgaon district in north Maharashtra and six persons were arrested, Directorate of Revenue Intelligence officials said.
'India easily remains one among the more attractive large economies, with high growth and stable/improving macros, as a top investment destination.' 'We are looking pretty good.'
A look at the top tweets from your favourite Bollywood celebrities.
'The mismatch between valuations and fundamentals is startling,' warns Devangshu Datta
Lack of clarity on whether manufacturing bans in Punjab, Uttarakhand, Himachal, Goa and Karnataka still in place
In a surprise announcement in April, Sun and Ranbaxy -- at that time owned by Japan's Daiichi -- declared an all-stock deal to create India's largest and world's fifth-largest drugmaker in an over $4 billion deal.
Sun Pharma's offer was tempting because Ranbaxy was too busy fighting fires in the US to concentrate on operations.
Competition in the US pharmaceutical market swelled in recent years, with increasing generic penetration.
Details on prices sought as 10 generic drugs become up to 83 times costlier in 6 months
Sun Pharmaceutical, which is growing its dermatology and ophthalmic specialty business in the US will spend $460 million on R&D.
With global markets pushing ahead, enthused by strengthening US jobs market, and also due to prospects of European rate hike, Indian markets also continued the march ahead.
It was a disturbing message in the sense that the regulatory framework is not clear enough and is not always applied in a convincing manner.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances